Hematology
Blood & lymphatic clinical trials
Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We’re tracking 5,083 recruiting studies in this area right now.
By phase
- Not applicable2,108
- Phase 21,116
- Phase 1823
- Phase 1/Phase 2481
- Phase 3349
- Phase 4127
- Phase 2/Phase 379
Top conditions
- Multiple Myeloma332
- Acute Myeloid Leukemia292
- Lymphoma182
- Sickle Cell Disease140
- Myelodysplastic Syndromes129
- Acute Lymphoblastic Leukemia122
- Chronic Lymphocytic Leukemia100
- Leukemia100
- Follicular Lymphoma74
- Hematologic Malignancy68
- Myelodysplastic Syndrome68
- Hodgkin Lymphoma67
- Mantle Cell Lymphoma62
- Anemia60
- Diffuse Large B Cell Lymphoma57
- Lymphedema50
- Non-Hodgkin Lymphoma49
- Small Lymphocytic Lymphoma49
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China148
- M.D. Anderson Cancer Center147
- National Cancer Institute (NCI)96
- The First Affiliated Hospital of Soochow University68
- Memorial Sloan Kettering Cancer Center64
- City of Hope Medical Center61
- Mayo Clinic61
- Assistance Publique - Hôpitaux de Paris46
- St. Jude Children's Research Hospital43
- Peking University People's Hospital41
Where studies are running
- California406
- Texas186
- Maryland149
- Alabama148
- Arizona124
- Florida111
- Massachusetts101
- New York98
- Ohio70
- Minnesota68
Recruiting studies5,083 total
- NCT05528887RecruitingPhase 1
CAR-T therapy study for relapsed or treatment-resistant blood cancers
This Phase 1 trial tests CAR-T cell therapy (immune cells modified to target cancer) in people whose blood cancers came back or didn’t respond to standard treatments. If you qualify, the study aims to see whether this treatment can fight the cancer and how safe it is.
Ningbo, ZhejiangAges 18–75 - NCT05528939Recruiting
Training attention skills for children after cancer
This trial tests a computer-based “attention-control training” program to see if it’s doable and helpful for children who finished treatment for acute lymphoblastic leukemia or a brain tumor. It also looks at how acceptable the program is for both kids and caregivers.
Washington D.C., District of ColumbiaAges 8–16 - NCT05529069RecruitingPhase 2
Testing pirtobrutinib plus venetoclax for relapsed mantle cell lymphoma
This Phase 2 trial tests how well the combination of pirtobrutinib and venetoclax works for people with mantle cell lymphoma that has come back or did not respond to treatment. It’s meant to help shrink the lymphoma and improve outcomes after prior therapies.
Houston, TexasAges 18 years+ - NCT05530096Recruiting
Genetic test to find minimal residual myeloma in remission
This study tests a genetic technology (ClonoSeq-based) to detect very small amounts of multiple myeloma that may remain after treatment. It may help doctors better track how well treatment is working and predict how the disease responds over time.
Montreal, QuebecAges 18 years+ - NCT05530421RecruitingPhase 2
Selinexor and Venetoclax with Dexamethasone for Myeloma
This trial studies a combination of selinexor, venetoclax, and dexamethasone to treat multiple myeloma that has returned or is resistant to prior treatments. It may help shrink the myeloma and improve disease control in people with a specific myeloma genetic marker (t(11;14)).
Coral Gables, FloridaAges 18 years+ - NCT05535855RecruitingPhase 1
UCD19 CAR T for adult ALL with MRD in remission
This early-phase study tests a personalized immune-cell treatment (CAR T) for adults with B-cell acute lymphoblastic leukemia (ALL) who still have tiny amounts of cancer detectable by a special test called MRD. It aims to improve outcomes for people who are in first remission but not completely “cancer-free” by MRD testing.
Aurora, ColoradoAges 18 years+ - NCT05535764RecruitingPhase 1
Test PegINFa after bone marrow transplant for myelofibrosis
This Phase 1 study tests PegINFa (after a bone marrow transplant) to see if it is safe and can help control myelofibrosis. You must be eligible for transplant and meet specific donor, timing, and health criteria before starting the study drug.
Salt Lake City, UtahAges 18 years+ - NCT05536349RecruitingPhase 2
Testing three drug combo for untreated CLL or CLL-related cancer
This Phase 2 study tests pirtobrutinib plus venetoclax plus obinutuzumab in people with untreated chronic lymphocytic leukemia (CLL) or CLL-related Richter transformation (RT). The goal is to see if this “triplet” combination works better and is safe enough to control the disease.
Houston, TexasAges 18 years+ - NCT05537896RecruitingPhase 2
Preventing infections in blood cancer patients with low white cells
This Phase 2 study tests whether taking Xerava (an antibiotic) can prevent serious infections in people who have prolonged low neutrophils after chemotherapy or transplant preparation. If it works, it may lower the risk of infections during the highest-risk period after treatment.
Morgantown, West VirginiaAges 18 years+ - NCT05540834RecruitingPhase 2
Testing blood-clot guidance for ICU patients with severe lung failure
This Phase 2 trial tests whether using a blood test that shows clotting strength and “clot breakdown time” can help guide treatment for people in the ICU with acute respiratory failure from infection. If you qualify, the team will use these blood results to decide on clot-related therapy and compare outcomes to standard care.
Liverpool, New South WalesAges 18–75 - NCT05541341Recruiting
Tisagenlecleucel outcomes study in relapsed B-cell blood cancers
This study looks at how safe and effective tisagenlecleucel is for people in Brazil who have certain B-cell blood cancers that came back or did not respond to treatment. You may be included if you already received tisagenlecleucel outside a research study and can consent to share your medical data.
Minas Gerais, Belo HorizonteAges birth–100 years - NCT05544019RecruitingPhase 1
Testing an investigational drug for mature B-cell cancers
This early (Phase 1) study tests SGR-1505, an experimental treatment, in people with certain mature B-cell cancers. It’s mainly designed to see how the drug works in the body and to check safety, and it may offer an option if standard treatments aren’t enough.
Gilbert, ArizonaAges 18 years+ - NCT05544968RecruitingPhase 1
CD30-targeted cell treatment for hard-to-treat blood cancers
This Phase 1 trial studies an experimental treatment that targets a marker called CD30 on cancer cells. It is for adults with certain relapsed or refractory CD30-positive blood cancers to see how well the treatment works and what side effects it causes.
Milwaukee, WisconsinAges 18 years+ - NCT05546593Recruiting
Ultrasound check for joint and tendon problems in gout
This study uses ultrasound to look for hidden changes in joints and tendons in people who have gout. It may help doctors better understand what ultrasound can show in gout, but it doesn’t sound like it’s testing a new medicine.
Boulogne-Billancourt, APHPAges 18 years+ - NCT05546723RecruitingPhase 1
Study drug for multiple myeloma after several prior treatments
This Phase 1 trial tests LMY-920 in people with multiple myeloma that has returned or stopped responding after multiple standard therapies. It’s meant to see if the treatment can work and to better understand its safety and side effects in this situation.
Cleveland, OhioAges 18 years+ - NCT05549102Recruiting
CBT therapy study for anxiety and brain circuit changes
This trial studies whether a specific form of talk therapy (CBT) changes brain activity in people with moderate anxiety. It may help your care team understand what works best and how brain “circuits” respond to treatment.
LondonAges 18–64 - NCT05549661RecruitingPhase 1
Onvansertib for hard-to-treat CMML and MDS/MPN
This Phase 1 study tests onvansertib to see if it can help people with repeat or treatment-resistant chronic myelomonocytic leukemia (CMML) and MDS/MPN overlap. It also studies side effects and gathers blood/bone marrow samples to better understand how the treatment works.
Rochester, MinnesotaAges 18 years+ - NCT05552222RecruitingPhase 3
New treatment combo study for newly diagnosed multiple myeloma
This phase 3 trial tests two different drug combinations to treat newly diagnosed multiple myeloma. It may help by aiming to control the cancer without using high-dose chemotherapy and stem cell transplant for people who can’t receive that approach.
Gilbert, ArizonaAges 18 years+ - NCT05553873Recruiting
Study links inflammation levels to outcomes in MPN patients
This study looks at inflammation-related lab markers in people with “Ph-negative” myeloproliferative neoplasms (like PV, ET, or PMF) to see how they relate to outcomes and response to treatment. It’s observational, meaning it gathers information from medical records without testing a new treatment.
BariAges 18–99 - NCT05554939RecruitingPhase 1/Phase 2
CAR-T cells targeting CD19 for relapsed B-cell lymphoma
This Phase 1/2 trial studies an “off-the-shelf” (allogeneic) immune-cell therapy that targets CD19, a marker on many B-cell lymphomas. It’s for adults whose lymphoma has come back or didn’t respond to prior treatment, aiming to shrink tumors and improve outcomes.
Beijing, Beijing MunicipalityAges 18–75 - NCT05556928Recruiting
Cancer and aging study for adults with blood cancers
This study builds a registry to learn how aging and “resilience” relate to outcomes in people with blood cancers. You may be asked to complete questionnaires during UAB visits, which can help researchers better understand needs in older adults.
Birmingham, AlabamaAges 50 years+ - NCT05557695Recruiting
Acalabrutinib patient study for early access CLL in the UK
This observational study follows adults in the UK who started acalabrutinib through an early access program for chronic lymphocytic leukemia (CLL). It aims to learn what happens in real-world care after starting the medicine.
AylesburyAges 18–130 - NCT05558124RecruitingPhase 1
Tested CPX-351 with gemtuzumab for newly diagnosed AML
This Phase 1 trial tests a new combination of CPX-351 plus gemtuzumab ozogamicin for people newly diagnosed with acute myeloid leukemia (AML). It aims to find a safe dose and see how well the treatment works, especially when the leukemia cells carry a target called CD33.
Tampa, FloridaAges 18–70 - NCT05561387RecruitingPhase 3
Drug combinations for newly diagnosed myeloma without transplant
This study compares different combinations of medicines for people newly diagnosed with multiple myeloma who cannot safely get a stem cell transplant. It aims to find which drug plan works best and is tolerable for people with “frail” or “intermediate fit” health.
Anchorage, AlaskaAges Any age
Common questions
- How many blood & lymphatic clinical trials are recruiting?
- Clin2 is tracking 5,083 recruiting hematology studies from the U.S. registry right now, out of 7,730 we cover in this area in total.
- What does “Blood & lymphatic” cover here?
- Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We group each study into blood & lymphatic based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a blood & lymphatic trial near me?
- Use the search to filter blood & lymphatic studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.